VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision...
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
- Posters to highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by...
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure - Sales and marketing efforts to focus on...
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
WEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study enrolled 92 adult
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH’s distribution footprint to include Cencora, Inc. as...
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
VP-315 was well tolerated with no reported treatment-related serious adverse events All patients treated with VP-315 had a reduction in tumor size with an...
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
WEST CHESTER, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Pharmaceuticals is Now Oversold (VRCA)
Verrica Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for VRCA
7 Short-Squeeze Stocks That Could Beat Down the Bears
Panic can be a cruel emotion, especially when the consequences are uncapped red ink.
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA...
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics...
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 ...
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Verrica Pharmaceuticals (NASDAQ:VRCA) just reported results for the first quart...